Holen Sie sich die Stockscreener-App
6.38
0.08%
0.00
Handel nachbörslich:
6.39
0.010
+0.16%
Schlusskurs vom Vortag:
$6.38
Offen:
$6.38
24-Stunden-Volumen:
2.43M
Relative Volume:
0.54
Marktkapitalisierung:
$1.23B
Einnahmen:
$71.80M
Nettoeinkommen (Verlust:
$-183.59M
KGV:
-6.0514
EPS:
-1.0543
Netto-Cashflow:
$-186.52M
1W Leistung:
+3.99%
1M Leistung:
-11.07%
6M Leistung:
-16.75%
1J Leistung:
+7.31%
1-Tages-Spanne:
$6.225
$6.44
1-Wochen-Bereich:
$6.02
$6.4999
52-Wochen-Spanne:
$5.02
$21.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
Firmenname
Wave Life Sciences Ltd
Sektor
Branche
Telefon
617-949-2900
Adresse
7 STRAITS VIEW, SINGAPORE
Compare WVE vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
6.38 | 1.23B | 71.80M | -183.59M | -186.52M | -1.0543 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-05 | Eingeleitet | BofA Securities | Buy |
| 2025-12-12 | Bestätigt | Wedbush | Outperform |
| 2025-12-09 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-07-28 | Eingeleitet | Oppenheimer | Outperform |
| 2025-07-16 | Eingeleitet | Citigroup | Buy |
| 2025-06-11 | Fortgesetzt | Raymond James | Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Eingeleitet | Wedbush | Outperform |
| 2025-02-25 | Eingeleitet | Jefferies | Buy |
| 2024-10-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-09-27 | Fortgesetzt | JP Morgan | Overweight |
| 2024-09-19 | Eingeleitet | B. Riley Securities | Buy |
| 2024-09-09 | Eingeleitet | JP Morgan | Overweight |
| 2024-05-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-12-19 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Eingeleitet | Raymond James | Outperform |
| 2023-05-24 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-31 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-11-01 | Eingeleitet | Guggenheim | Buy |
| 2019-07-15 | Eingeleitet | Cowen | Market Perform |
| 2019-04-17 | Bestätigt | H.C. Wainwright | Buy |
| 2018-08-07 | Eingeleitet | Stifel | Buy |
| 2018-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-19 | Bestätigt | Mizuho | Buy |
| 2017-02-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-11-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-12-07 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-07 | Eingeleitet | Jefferies | Buy |
| 2015-12-07 | Eingeleitet | Leerink Partners | Outperform |
| 2015-12-07 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
Alle ansehen
Wave Life Sciences Ltd Aktie (WVE) Neueste Nachrichten
Should WVE-006’s RNA-Editing AAT Data Shift the Risk-Reward Calculus for Wave Life Sciences (WVE) Investors? - Yahoo Finance
Wave Life Sciences (WVE) Valuation Check After Sharp Share Price Weakness - simplywall.st
WAVE Life Sciences Analyst Ratings and Price Targets | NASDAQ:WVE - Benzinga
WVE Stock Price, Quote & Chart | WAVE LIFE SCIENCES LTD (NASDAQ:WVE) - ChartMill
Wells Fargo Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Wave Life Sciences (WVE) Is Down 11.4% After Positive WVE-006 AATD Data and Accelerated Path Update - simplywall.st
Wave Life Sciences: 'Strong Buy' On DMD NDA Filing WVE-N531 And Released AATD Data - Seeking Alpha
WVE Maintained by Wells Fargo -- Price Target Raised to $14.00 - GuruFocus
Wave Life Sciences Is Maintained at Overweight by Wells Fargo - Moomoo
CCORF Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $43 - Moomoo
WVE: Advancing siRNA and RNA editing therapies with strong clinical data and regulatory momentum - TradingView
Wells Fargo raises Wave Life Sciences price target on AATD data - Investing.com Australia
Wells Fargo Maintains Wave Life Sciences(WVE.US) With Buy Rating, Cuts Target Price to $14 - Moomoo
Wave Life Sciences Signals Momentum in Earnings Call - TipRanks
Wave Life Sciences crashes deep into oversold territory as obesity drug data disappoints. Should you buy the dip? - MSN
WVE Maintained by HC Wainwright & Co. -- Price Target Lowered to $13 - GuruFocus
Wave Life Sciences' New Data From AATD Study Met Expectations, Wedbush Says - Moomoo
Cantor Fitzgerald reiterates Overweight on Wave Life Sciences stock By Investing.com - Investing.com South Africa
Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1 - Yahoo Finance UK
A Quick Look at Today's Ratings for Wave Life Sciences(WVE.US), With a Forecast Between $13 to $15 - Moomoo
Wave Life Sciences stock price target lowered to $13 by H.C. Wainwright - Investing.com South Africa
Cantor Fitzgerald reiterates Overweight on Wave Life Sciences stock - Investing.com
H.C. Wainwright Maintains Wave Life Sciences(WVE.US) With Buy Rating, Cuts Target Price to $13 - Moomoo
Wave Life Sciences Announces Positive RestorAATion-2 Trial Results for WVE-006, a Novel RNA Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD) - Minichart
Wave Life Sciences Ltd. (WVE) Shareholder/Analyst CallSlideshow (NASDAQ:WVE) 2026-05-18 - Seeking Alpha
WVE: WVE-006 delivers robust Z-AAT reduction and M-AAT restoration with strong safety in PiZZ AATD - TradingView
Wave Life Sciences reports phase 1b/2a trial data for AATD therapy By Investing.com - Investing.com South Africa
WVE: WVE-006 delivers robust, durable AAT correction and dynamic response in ZZ AATD with strong safety - TradingView
WVE Stock Edges Up After Positive Early Data For Rare Disease Drug - Stocktwits
WVE: WVE-006 achieved up to 71% Z-AAT reduction and restored protective M-AAT levels in AATD - TradingView
Wave Life Sciences advances WVE-006 RNA editing trial - TipRanks
Wave Life Sciences (WVE) Reports Progress on WVE-006 in Clinical Trial - GuruFocus
Wave Life Sciences reports phase 1b/2a trial data for AATD therapy - Investing.com
Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing - TradingView
WVE-006 AATD trial shows strong biomarker gains for Wave Life Sciences (WVE) - Stock Titan
Wave Life Sciences Reports Promising Data for WVE-006 in Treating Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency, Anticipates FDA Feedback in Mid-2026 - Quiver Quantitative
Experimental RNA-editing shot aims to treat lung and liver damage in alpha-1 - Stock Titan
Wave Life Sciences (WVE) price target decreased by 15.26% to 23.97 - MSN
Wave Life Sciences Ltd.Ordinary Shares (NQ: WVE - FinancialContent
Wedbush Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Wave Life Sciences ATS Data Could Support RNA Editing Platform, Wedbush Says - Moomoo
Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight - GlobeNewswire Inc.
Wave Life Sciences stock (SG1V20936237): Starts Phase 1 trial for one-time GLP-1 gene therapy - AD HOC NEWS
Wave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference - The Manila Times
Adage (NASDAQ: WVE) discloses 1,000,000-share stake, 0.53% of class - Stock Titan
Wave Life Sciences (WVE) Attracts Positive Attention Amid Compet - GuruFocus
Surging Q1 Revenue And Narrower Losses Might Change The Case For Investing In Wave (WVE) - Sahm
Finanzdaten der Wave Life Sciences Ltd-Aktie (WVE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Wave Life Sciences Ltd-Aktie (WVE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 27 '26 |
Buy |
6.43 |
2,495,623 |
16,046,856 |
26,004,414 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 30 '26 |
Buy |
6.50 |
971,091 |
6,312,092 |
26,975,505 |
| Francis Chris | See Remarks |
Feb 26 '26 |
Option Exercise |
4.28 |
33,194 |
141,920 |
79,767 |
| Francis Chris | See Remarks |
Feb 26 '26 |
Sale |
15.05 |
33,194 |
499,593 |
61,867 |
| Moran Kyle | Chief Financial Officer |
Feb 09 '26 |
Sale |
13.45 |
3,588 |
48,259 |
134,385 |
| BOLNO PAUL | President and CEO |
Feb 09 '26 |
Sale |
13.45 |
10,480 |
140,956 |
275,520 |
| Francis Chris | See Remarks |
Feb 09 '26 |
Sale |
13.45 |
1,883 |
25,326 |
61,867 |
| Vargeese Chandra | See Remarks |
Feb 09 '26 |
Sale |
13.45 |
3,228 |
43,417 |
408,246 |
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):